Shanghai Shyndec Pharmaceutical Co Ltd
SSE:600420
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.96
14.14
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co Ltd
PP&E Gross
Shanghai Shyndec Pharmaceutical Co Ltd
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shanghai Shyndec Pharmaceutical Co Ltd
SSE:600420
|
PP&E Gross
¥5.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
14%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
PP&E Gross
¥3.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
PP&E Gross
¥854.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
26%
|
CAGR 10-Years
11%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
PP&E Gross
¥7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
PP&E Gross
¥3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
PP&E Gross
¥534.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shanghai Shyndec Pharmaceutical Co Ltd
Glance View
Shanghai Shyndec Pharmaceutical Co., Ltd. principally engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 11,937 full-time employees. The company went IPO on 2004-06-16. The firm's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The firm also offers topical preparations, such as gynecological suppositories and dermatology preparations.
See Also
What is Shanghai Shyndec Pharmaceutical Co Ltd's PP&E Gross?
PP&E Gross
5.8B
CNY
Based on the financial report for Jun 30, 2024, Shanghai Shyndec Pharmaceutical Co Ltd's PP&E Gross amounts to 5.8B CNY.
What is Shanghai Shyndec Pharmaceutical Co Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 10Y
14%
Over the last year, the PP&E Gross growth was -6%. The average annual PP&E Gross growth rates for Shanghai Shyndec Pharmaceutical Co Ltd have been -4% over the past three years , -2% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
